Qube Research & Technologies (QRT)
ENTA icon

Qube Research & Technologies (QRT)’s Enanta Pharmaceuticals ENTA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48M Buy
116,961
+84,572
+261% +$1.13M ﹤0.01% 2324
2025
Q4 		$511K Buy
32,389
+20,469
+172% +$260K ﹤0.01% 2798
2025
Q3 		$143K Sell
11,920
-71,992
-86% -$575K ﹤0.01% 3003
2025
Q2 		$634K Sell
83,912
-3,955
-5% -$23.8K ﹤0.01% 2618
2025
Q1 		$485K Sell
87,867
-73,812
-46% -$456K ﹤0.01% 2556
2024
Q4 		$930K Buy
161,679
+40,660
+34% +$390K ﹤0.01% 2204
2024
Q3 		$1.25M Buy
121,019
+61,235
+102% +$801K ﹤0.01% 1949
2024
Q2 		$775K Sell
59,784
-42,841
-42% -$578K ﹤0.01% 1992
2024
Q1 		$1.79M Sell
102,625
-86,203
-46% -$1.14M ﹤0.01% 1824
2023
Q4 		$1.78M Buy
188,828
+75,156
+66% +$700K ﹤0.01% 1583
2023
Q3 		$1.27M Buy
113,672
+68,076
+149% +$1.1M ﹤0.01% 1612
2023
Q2 		$976K Buy
45,596
+29,942
+191% +$883K ﹤0.01% 1312
2023
Q1 		$633K Sell
15,654
-7,742
-33% -$370K ﹤0.01% 1473
2022
Q4 		$1.09M Sell
23,396
-11,303
-33% -$515K 0.01% 1190
2022
Q3 		$1.8M Buy
34,699
+29,414
+557% +$1.72M 0.01% 972
2022
Q2 		$250K Sell
5,285
-4,018
-43% -$218K ﹤0.01% 1638
2022
Q1 		$662K Buy
9,303
+824
+10% +$53.6K 0.01% 1391
2021
Q4 		$634K Buy
+8,479
New +$665K ﹤0.01% 1450
2020
Q1 		– Sell
-8,096
Closed -$500K – 1263
2019
Q4 		$500K Buy
+8,096
New +$502K 0.02% 950

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ENTA Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Enanta Pharmaceuticals (ENTA) stake by 261% in Q1 2026, buying an estimated $1.13M and bringing the position to 116,961 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Qube Research & Technologies (QRT) first reported a position in ENTA in Q4 2019 and has held it in 19 quarters since. The position peaked at $1.8M in Q3 2022. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Qube Research & Technologies (QRT) held 116,961 shares of Enanta Pharmaceuticals worth $1.48M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 84,572 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
  • Enanta Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2324 holding.
  • Qube Research & Technologies (QRT) first reported a position in Enanta Pharmaceuticals in Q4 2019 and has held it in 19 quarters since.
  • Qube Research & Technologies (QRT)'s Enanta Pharmaceuticals position peaked at $1.8M in Q3 2022.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.